Editor’s Insight
Expanding drug quality testing beyond a single laboratory reduces bottlenecks and strengthens regulatory oversight. For suppliers and healthcare providers, this signals faster approvals and fewer supply disruptions, while reinforcing confidence in medicine safety through improved coordination among public institutions.
Full Story:
The Health Ministry has started formal steps to widen drug quality testing by using multiple state laboratories under a coordinated system.
Health and Mass Media Minister Nalinda Jayatissa chaired a high-level discussion on improving the scale and speed of drug quality testing. Officials said reliance on a single laboratory limits capacity and delays decisions.

The National Medicines Regulatory Authority will continue to lead regulatory oversight. At the same time, other government laboratories may support testing work to increase volumes and reduce delays.
Officials stressed the need for better coordination between testing institutions. They said improved data sharing will help regulators detect quality risks earlier and respond faster.
The Minister directed officials to prioritise medicines with known quality issues. This approach aims to protect patient safety while avoiding supply disruptions in hospitals and pharmacies.
Senior officials from the Ministry of Health, the Director General of Health Services, and the Ministry of Science and Technology attended the meeting.
The Ministry plans to develop this initiative into a structured national programme. Authorities expect it to strengthen the reliability of the pharmaceutical supply system and improve public confidence in medicine safety.
Key outcomes of Indian EAM S. Jaishankar’s visit to Sri Lanka
Last modified: December 25, 2025




